VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen
Short Communication VP-16, Ifosfamide, Methotrexate, Non-Hodgkin's Lymphoma, LNH 84
Received:
Accepted:
- 35 Downloads
- 3 Citations
Summary
A total of 20 patients with intermediate or highgrade non-Hodgkin's lymphomas who failed to LNH 84 regimen were treated with a combination of VP 16, ifosfamide and methotrexate (VIM regimen). Nineteen patients are evaluable for response. Eight patients (42%) achieved complete responses and four (21%) attained partial responses. Most of the complete responders are still in remission with a follow-up of more than 30 months for 5 patients.
Keywords
Lymphoma Cancer Research Methotrexate Partial Response Combination Chemotherapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
- 1.Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60: 693–697Google Scholar
- 2.Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5: 407–412Google Scholar
- 3.Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N (1989) LNH 84 regimen: a multicentre study of intensive chemotherapy in 749 patients with aggressive malignant lymphoma. J Clin Oncol (in press)Google Scholar
- 4.Steinke B, Krüger HU, Kraft A, Arnold H, Heim ME, Günther E, Busch FW (1987) Etoposide, ifosfamide, methotrexate and bleomycin (VIM-Bleo) in CHOP-resistant non-Hodgkin's lymphomas. Proc ECCO 4 (Abstr 1011)Google Scholar
Copyright information
© Springer-Verlag 1989